| |
| |
|
| Insider
Information: |
Torley Helen |
| Relationship: |
Director |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
683,004 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$26,942,484 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
683,004 |
|
|
| Total
Value |
$26,942,484 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -28.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Onyx Pharmaceuticals Inc |
ONXX |
EVP, Chief Commercial ... |
2013-10-01 |
0 |
2011-08-29 |
0 |
Premium* |
|
|
Halozyme Therapeutics Inc |
HALO |
|
2024-02-16 |
676,744 |
2014-09-16 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Quest Diagnostics Inc |
DGX |
Director |
2021-05-25 |
6,260 |
2018-05-15 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2024-02-16 |
4 |
D |
$36.10 |
$735,068 |
D/D |
(20,362) |
676,744 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2024-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,884 |
685,814 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2024-02-15 |
4 |
D |
$35.91 |
$885,361 |
D/D |
(24,655) |
659,222 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
32,781 |
676,841 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,092 |
651,096 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2024-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,281 |
654,947 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2024-02-10 |
4 |
D |
$35.49 |
$601,307 |
D/D |
(16,943) |
638,004 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-31 |
4 |
AS |
$42.82 |
$428,170 |
D/D |
(10,000) |
623,666 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-31 |
4 |
OE |
$13.87 |
$138,700 |
D/D |
10,000 |
633,666 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-30 |
4 |
OE |
$13.87 |
$138,700 |
D/D |
10,000 |
633,666 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-30 |
4 |
AS |
$42.85 |
$428,540 |
D/D |
(10,000) |
623,666 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-29 |
4 |
AS |
$42.40 |
$424,020 |
D/D |
(10,000) |
623,666 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-29 |
4 |
OE |
$13.87 |
$138,700 |
D/D |
10,000 |
633,666 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-17 |
4 |
AS |
$43.18 |
$431,820 |
D/D |
(10,000) |
623,666 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-17 |
4 |
OE |
$13.87 |
$138,700 |
D/D |
10,000 |
633,666 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-16 |
4 |
OE |
$13.87 |
$138,700 |
D/D |
10,000 |
633,666 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-16 |
4 |
AS |
$43.53 |
$435,320 |
D/D |
(10,000) |
623,666 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-15 |
4 |
AS |
$43.77 |
$437,680 |
D/D |
(10,000) |
623,666 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-15 |
4 |
OE |
$13.87 |
$138,700 |
D/D |
10,000 |
633,666 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-07-27 |
4 |
OE |
$13.87 |
$138,700 |
D/D |
10,000 |
633,666 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-07-27 |
4 |
AS |
$43.79 |
$437,900 |
D/D |
(10,000) |
623,666 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-07-26 |
4 |
AS |
$42.69 |
$426,890 |
D/D |
(10,000) |
623,666 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-07-26 |
4 |
OE |
$13.87 |
$138,700 |
D/D |
10,000 |
633,666 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-07-25 |
4 |
AS |
$42.80 |
$427,960 |
D/D |
(10,000) |
623,666 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-07-25 |
4 |
OE |
$13.87 |
$138,700 |
D/D |
10,000 |
633,666 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
